@article{7790035010e343f792f54b791853ed85,
title = "Chimeric antigen receptors for T-cell malignancies",
abstract = "Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.",
keywords = "Chimeric antigen receptors (CARs), Immunotherapy, Non-Hodgkin lymphoma, T cell malignancy, T-cells",
author = "Scherer, {Lauren D.} and Malcolm Brenner and Maksim Mamonkin",
note = "Funding Information: This work was supported by the National Institutes of Health, National Cancer Institute (P50 CA126752). Funding Information: PP is supported by Italian Ministry for University and Research (MIUR, Rita Levi-Montalcini program for young researchers, 2014). MM is funded by Fondazione Umberto Veronesi. AM is funded by Fondazione Umberto Veronesi and Associazione Italiana Ricerca sul Cancro and Fondazione Cassa di Risparmio di Firenze (grant 19515). Publisher Copyright: Copyright {\textcopyright} 2019 Scherer, Brenner and Mamonkin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
doi = "10.3389/fonc.2019.00126",
language = "English (US)",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "MAR",
}